Spravato

Spravato (esketamine) is a prescription nasal spray used alongside oral antidepressants for treatment-resistant depression. It is administered under medical supervision due to its unique mechanism. Esketamine works differently from traditional antidepressants, targeting NMDA receptors in the brain.

Spravato (esketamine) is prescribed for adults with treatment-resistant depression who have not responded to at least two different antidepressants. It is used alongside an oral antidepressant to help improve symptoms of major depressive disorder. Esketamine is also indicated for acute suicidal ideation or behavior in adults with major depressive disorder. This medication is not a first-line treatment and is typically reserved for cases where other options have failed.

Spravato (esketamine) may help reduce symptoms of depression over time with regular use. Some users report feeling a sense of detachment or mild dissociation shortly after administration, which is usually temporary. The effects of esketamine can vary, and it may take several weeks to notice improvements in mood or outlook.

Spravato (esketamine) is administered in a certified healthcare setting to monitor for potential side effects. Patients should not drive or operate machinery until the day after treatment due to possible drowsiness or dizziness. It is important to inform the healthcare provider about all medications and medical conditions before starting esketamine. Avoid alcohol and other sedatives during treatment.

Spravato (esketamine) may interact with central nervous system depressants, such as alcohol, benzodiazepines, or opioids, increasing the risk of sedation. Combining esketamine with MAO inhibitors or certain other antidepressants may require careful monitoring. CYP3A4 inhibitors or inducers can affect esketamine levels in the body, so inform your healthcare provider about all medications you are taking.